Metabolic Evaluation and Medical Management of Upper Urinary Tract Stone Disease: Guidelines from the Scandinavian Cooperative Group for Urinary Stones

REFERENCES

• Rya11 RL, Marshall VR. The investigation and manage-ment of idiopathic urolithiasis. In: Wickham JEA, Buck AC, editors. Renal tract stone. Metabolic basis and clinical practice. Edinburgh: Churchill Livingstone, 1990: 307–31.
   Google Scholar
• Goldfarb S. Dietary factors in the pathogenesis and prophylaxis of calcium nephrolithiasis. Kidney Int 1988; 34: 544–55.
   PubMed Web of Science ®Google Scholar
• Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328: 833–8.
   PubMed Web of Science ®Google Scholar
• Tiselius H-G. Metabolic evaluation of patients with stone disease. Urol Int 1997; 59: 131–41.
   PubMed Web of Science ®Google Scholar
• Tiselius H-G, Larsson L. Urinary excretion of urate in patients with calcium oxalate stone disease. Urol Res 1983; 11: 279–83.
   Google Scholar
• Johansson G. Magnesium metabolism. Studies in health, primary hyperparathyroidism and renal stone disease. Scand J Urol Nephrol 1979; Suppl 51: 1–73.
   Google Scholar
• Bek-Jensen H, Tiselius H-G. Stone formation and urine composition in calcium stone formers without medical treatment. Eur Urol 1989; 16: 144–50.
   Google Scholar
• Osther PJ. Hyperoxaluria in idiopathic calcium nephro-lithiasis. What are the limits? Scand J Urol Nephrol: in press.
   Google Scholar
• Preminger GM. Renal calculi: pathogenesis, diagnosis, and medical therapy. Semin Nephrol 1992; 12: 200–16.
   PubMed Web of Science ®Google Scholar
• Sakhaee K, Nicar M, Hill K, Pak CYC. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 1983; 24: 348–52.
   PubMed Web of Science ®Google Scholar
• Pak CYC, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986; 30: 422–8.
   Google Scholar
• Leumann E, Hoppe B, Neuhaus T. Management of primary hyperoxaluria: efficacy of oral citrate adminis-tration. Pediatr Nephrol 1993; 7: 207–11.
   Google Scholar
• Tiselius H-G, Ahlstrand C, Lundström B, Nilsson MA. [14C]Oxalate absorption by normal persons, calcium oxalate stone formers, and patients with surgically disturbed intestinal function. Clin Chem 1981; 27: 1682–5.
   Google Scholar
• Osther PJ, Bollerslev J, Hansen AB, Engel K, Kildeberg P. Pathophysiology of incomplete renal tubular acidosis in recurrent renal stone formers: evidence of disturbed calcium, bone and citrate metabolism. Urol Res 1992; 21: 169–73.
   Google Scholar
• Preminger GM, Sakhaee K, Skurla C, Pak CYC. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 1985; 134: 20–3.
   PubMed Web of Science ®Google Scholar
• Lindell A, Denneberg T, Edholm E, Jeppson J-0. The effect of sodium intake on cystinuria with or without tiopronin treatment. Nephron 1995; 71: 407–15.
   Google Scholar
• Sakhaee K. Cystinuria: pathogenesis and treatment. Miner Electrolyte Metab 1994; 20: 413–23.
   Google Scholar
• Chow GK, Streem SB. Medical treatment of cystinuria: results of contemporary clinical practice. J Urol 1996; 156: 1576–8.
   PubMed Web of Science ®Google Scholar
• Hedelin H, Brorsson JE, Grenabo L, Pettersson S. Ureaplasma urealyticum and upper urinary tract stones. Br J Urol 1984; 56: 244–9.
   PubMedGoogle Scholar
• Grenabo L, Hedelin H, Pettersson S. The severity of infection stones compared to other stones in the upper urinary tract. Scand J Urol Nephrol 1985; 19: 285–9.
   Google Scholar
• Segura JVV, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, Macaluso JN, McCullough DL. Nephrolithiasis clinical guidelines panel summary report on the management of staghorn calculi. J Urol 1994; 151: 1648–51.
   PubMed Web of Science ®Google Scholar
• Wall I, Tiselius H-G. Long-term acdification of urine in patients treated for infected renal stones. Urol Int 1990; 45: 336–41.
   Google Scholar
• Osther PJ, Mathiasen H, Hansen AB, Nissen HM. Urinary acidification and urinary excretion of calcium and citrate in women with bilateral medullary sponge kidney. Urol Int 1994; 52: 126–30.
   PubMed Web of Science ®Google Scholar
• Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 1983; 130: 1115–8.
   Google Scholar
• Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5 year randomized prospective study. J Urol 1996; 155: 839–43.
   PubMed Web of Science ®Google Scholar
• Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996; 144: 25–33.
   PubMed Web of Science ®Google Scholar
• Osther PJ, Norgaard JR, Engel K, Kildeberg P. Effect of acute acid loading on the risk of calcium phosphate and calcium oxalate crystallization in urine. Scanning Microsc 1994; 8: 63–9.
   Google Scholar
• Hess B, Casez J-P, Takkinen R, Ackermann D, Jaeger P. Relative hypoprathyroidism and calcitriol up-regulation in hypercalciuric calcium renal stone formers-impact of nutrition. Am J Nephrol 1993; 13: 18–26.
   Google Scholar
• Wikström B, Backman U, Danielsen BG, Fellström B, Johansson G, Ljunghall S. Ambulatory diagnostic evaluation of 389 recurrent renal stone formers. Klin Wochenschr 1983; 61: 85–90.
   Google Scholar
• Ljunghall S. Waern AU. Urinary electrolytes in renal stone formers and healthy subjects. Scand J Urol Nephrol 1977; Suppl 41: 55–76.
   Google Scholar
• Pak CYC. Physiological basis for absorptive and renal hypercalciuria. Am J Physiol 1979; 237: F415–23.
   PubMedGoogle Scholar
• Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous re-currence but magnesium hydroxide does not. J Urol 1988; 139: 679–83.
   PubMed Web of Science ®Google Scholar
• Preminger GM, Pak CYC. Eventual attenuation of hypocalciuric response to hydrochlorothiazide in ab-sorptive hypercalciuria. J Urol 1987; 137: 1104–9.
   PubMed Web of Science ®Google Scholar
• Pak CYC, Peterson R, Sakhaee K, Preminger GM. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephro-lithiasis. Am J Med 1986; 79: 284–8.
   Web of Science ®Google Scholar
• Tiselius H-G, Fomander A-M, Nilsson M-A. Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microse 1993; 7: 381–90.
   Google Scholar
• Osther PJ. Citrate and kidney stones. J Dan Med Assoc 1993; 155: 3835–9.
   Google Scholar
• Pak CYC, Fuller C, Sakhaee K, Preminger GM, Brtitton F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 1985; 134: 11–9.
   Google Scholar
• Hofbauer J, H6barth K, Szabo N, Marberger M. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis—a prospective randomized study. Br J Urol 1994; 73: 362–5.
   PubMedGoogle Scholar
• Barcelo P. Wuhl O, Servitge E, Rousaud A, Pak CYC. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic nephrolithiasis. J Urol 1993; 150: 1761–4.
   Google Scholar
• Ettinger B, Pak CYC, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997; 158: 2069–73.
   Google Scholar
• Koenig K, Padalino P. Alexandrides G, Pak CYC. Bioavailability of potassium and magnesium and citraturic response from potassium-magnesium citrate. J Urol 1991; 145: 330–4.
   PubMed Web of Science ®Google Scholar